Cover Image
市場調查報告書

耳鳴:開發中產品分析

Tinnitus - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200496
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
耳鳴:開發中產品分析 Tinnitus - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 59 Pages
簡介

耳鳴是指耳邊和腦中感到各種噪音的症狀。人們生活中常會感到耳鳴。其原因有老化造成的聽覺退化,曝露在巨大的噪音下,外耳道的耳垢妨礙聽力、抽煙及耳骨異常增長等。症狀有聽見鈴聲、耳鳴、叫聲、敲擊聲、咻咻的風聲、刷的聲音、嘰嘰的聲音,低音或高頻音等雜音。

本報告提供全球各國的耳鳴治療用的開發中產品的開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等資訊。

簡介

  • 調查範圍

耳鳴概要

治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

耳鳴:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

耳鳴治療藥的開發企業

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co KgaA
  • Otonomy Inc
  • SciFluor Life Sciences LLC
  • Sound Pharmaceuticals Inc

藥物簡介

  • AM-102
  • AUT-3
  • D-Methionine
  • esketamine hydrochloride
  • gacyclidine SR
  • GW-1
  • GW-2
  • neramexane mesylate
  • RL-81
  • SF-0034
  • Small Molecule to Activate KCNQ for Tinnitus
  • Small Molecules to Activate Kv7.2 for Neuropathic Pain, Epilepsy and Tinnitus
  • Small Molecules to Activate Neurotrophic Factor for Tinnitus
  • Small Molecules to Inhibit TNF-Alpha for Tinnitus
  • SPI-1005
  • tetrandrine

耳鳴:暫停中的計劃

耳鳴:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9176IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tinnitus - Overview
    • Tinnitus - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tinnitus - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tinnitus - Companies Involved in Therapeutics Development
    • AudioCure Pharma GmbH
    • Auris Medical Holding AG
    • Knopp Biosciences LLC
    • Merz Pharma GmbH & Co KgaA
    • Otonomy Inc
    • SciFluor Life Sciences LLC
    • Sound Pharmaceuticals Inc
  • Tinnitus - Drug Profiles
    • AM-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-Methionine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gacyclidine SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neramexane mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RL-81 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0034 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate KCNQ for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Kv7.2 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Neurotrophic Factor for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-1005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetrandrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tinnitus - Dormant Projects
  • Tinnitus - Product Development Milestones
    • Featured News & Press Releases
      • Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
      • Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
      • Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback
      • Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus
      • Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update
      • Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
      • Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
      • Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
      • Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
      • Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
      • Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City
      • Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus
      • Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
      • Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
      • Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tinnitus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2017
  • Tinnitus - Pipeline by Auris Medical Holding AG, H1 2017
  • Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2017
  • Tinnitus - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2017
  • Tinnitus - Pipeline by Otonomy Inc, H1 2017
  • Tinnitus - Pipeline by SciFluor Life Sciences LLC, H1 2017
  • Tinnitus - Pipeline by Sound Pharmaceuticals Inc, H1 2017
  • Tinnitus - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Tinnitus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top